Sigrima 420mg Pertuzumab Injection

Sigrima 420mg Pertuzumab Injection is a prescription targeted therapy used in the treatment of HER2-positive breast cancer, including early-stage and metastatic forms of the disease. It contains Pertuzumab, a monoclonal antibody that works by binding to the HER2 receptor on cancer cells, helping to block signals that promote tumor growth and survival. When used in combination with other anti-HER2 therapies and chemotherapy, Sigrima 420mg Pertuzumab Injection can help slow disease progression and improve treatment outcomes. Administered as an intravenous infusion under the supervision of an oncology specialist, it requires regular monitoring to assess effectiveness and manage potential side effects. Patients should use Sigrima 420mg Pertuzumab Injection only as prescribed by their healthcare provider as part of a comprehensive cancer treatment plan.